UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

Journal of clinical oncology, 2012-05, Vol.30 (13), p.1484-1491

2012

Volltextzugriff (PDF)

Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned

Therapeutic innovation & regulatory science, 2023-07, Vol.57 (4), p.899-910

2023

Volltextzugriff (PDF)

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

BMC cancer, 2012-09, Vol.12 (1), p.415-415, Article 415

2012

Volltextzugriff (PDF)

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

Blood advances, 2018-07, Vol.2 (13), p.1633-1644

2018

Volltextzugriff (PDF)

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

European journal of cancer (1990), 2013-01, Vol.49 (2), p.312-322

2013

Volltextzugriff (PDF)

Statistical and Operational Considerations for 2-Stage Adaptive Designs with Simultaneous Evaluation of Overall and Marker-Selected Populations in Oncology Confirmatory Trials

Therapeutic innovation & regulatory science, 2022-07, Vol.56 (4), p.552-560

2022

Volltextzugriff (PDF)

Patient‐reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

HemaSphere, 2023-11, Vol.7 (11), p.e966-n/a

2023

Volltextzugriff (PDF)

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2―Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Clinical cancer research, 2013-05, Vol.19 (10), p.2745-2754

2013

Volltextzugriff (PDF)

Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status

Stroke (1970), 2006-06, Vol.37 (6), p.1385-1390

2006

Volltextzugriff (PDF)

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

Clinical lymphoma, myeloma and leukemia, 2020-01, Vol.20 (1), p.e30-e37

2020

Volltextzugriff (PDF)

Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis

Blood, 2021-11, Vol.138 (Supplement 1), p.3638-3638

2021

Volltextzugriff (PDF)

Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS8066-TPS8066

2020

Volltextzugriff (PDF)

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Blood, 2022-11, Vol.140 (Supplement 1), p.9677-9680

2022

Volltextzugriff (PDF)

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Blood, 2020-11, Vol.136 (Supplement 1), p.51-52

2020

Volltextzugriff (PDF)

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Blood, 2017-12, Vol.130, p.4057-4057

2017

Volltextzugriff (PDF)

Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type ( MYD88 WT ) Waldenström macroglobulinemia (WM)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e20056-e20056

2020

Volltextzugriff (PDF)

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)

JOURNAL OF CLINICAL ONCOLOGY, 2020, Vol.38 (15_suppl), p.8007-8007

2020

Volltextzugriff (PDF)

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Blood, 2017-12, Vol.130, p.152-152

2017

Volltextzugriff (PDF)

Design and rationale of FOCUS

BMC cancer, 2012-09, Vol.12

2012

Volltextzugriff (PDF)

Making sense of DNA microarray data

Methods in molecular medicine, 2005, Vol.113, p.293

2005

Volltextzugriff (PDF)

Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib

Blood, 2011-11, Vol.118 (21), p.1877-1877

2011

Volltextzugriff (PDF)

Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2015-11, Vol.15 (11), p.680-686

2015

Volltextzugriff (PDF)

Development of a Robust and User-Friendly Method for Leukemia Classification Using Microarrays

Blood, 2006-11, Vol.108 (11), p.4304-4304

2006

Volltextzugriff (PDF)

A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling

Blood, 2005-11, Vol.106 (11), p.757-757

2005

Volltextzugriff (PDF)

Mussel‐Inspired Polydopamine‐Treated Reinforced Composite Membranes with Self‐Supported CeOx Radical Scavengers for Highly Stable PEM Fuel Cells

Advanced functional materials, 2019-01, Vol.29 (3), p.n/a

2019

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(32)
Tagungsberichte
(2)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned

Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer

Statistical and Operational Considerations for 2-Stage Adaptive Designs with Simultaneous Evaluation of Overall and Marker-Selected Populations in Oncology Confirmatory Trials

Patient‐reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study

Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2―Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Association of phosphodiesterase 4D polymorphisms with ischemic stroke in a US population stratified by hypertension status

Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis

Baseline Serum Ferritin Differentially Predicts W24 Transfusion Independence Response for Momelotinib and Ruxolitinib in Patients with Myelofibrosis

Trial in progress: a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma intolerant of prior treatment with ibrutinib

The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 Momentum Study

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type ( MYD88 WT ) Waldenström macroglobulinemia (WM)

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM)

Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin's Lymphoma

Design and rationale of FOCUS

Making sense of DNA microarray data

Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib

Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma

Development of a Robust and User-Friendly Method for Leukemia Classification Using Microarrays

A Multi-Center and Multi-National Program To Assess the Clinical Accuracy of the Molecular Subclassification of Leukemia by Gene Expression Profiling

Mussel‐Inspired Polydopamine‐Treated Reinforced Composite Membranes with Self‐Supported CeOx Radical Scavengers for Highly Stable PEM Fuel Cells

Suchergebnisse filtern